Refractory Duodenal Ulcer

  • J. W. Rademaker
  • R. H. Hunt
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 99)


The term “refractory duodenal ulcer” has been used since the introduction of the H2 receptor antagonist cimetidine and represents the more severe end of a disease spectrum for which the underlying pathophysiological mechanisms remain complex and poorly understood.


Duodenal Ulcer Acid Secretion Ulcer Healing Duodenal Ulcer Patient Duodenal Ulcer Healing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aadland E, Berstad A (1979) Parietal and chief cell sensitivity to histamine and pentagastrin stimulation before and after ranitidine treatment in healthy subjects. Scand J Gastroenterol 14:933–938.PubMedGoogle Scholar
  2. Aadland E, Berstad A, Semb LS (1977) Effect of cimetidine on pentagastrin stimulated gastric secretion in healthy man. Scand J Gastroenterol 12:501–506.PubMedGoogle Scholar
  3. Achord JL (1981) Gastric pepsin and acid secretion in patients with acute and healed duodenal ulcer. Gastroenterology 81:15–18.PubMedGoogle Scholar
  4. Aly A, Emas S (1982) Sensitivity of the oxyntic and peptic cells to pentagastrin in duodenal ulcer patients and healthy subjects with similar secretory capacity. Digestion 25:88–95.PubMedGoogle Scholar
  5. Amdrup E (1988) Surgery and its sequelae. In: Piper DW (ed) Balliere’s clinical gastroenterology. Balliere Tindall, London, pp 699–710.Google Scholar
  6. Amouretti M, Ansenay M, Bader JP, Baillet J, Bel A, Belaiche J, Benzenou A, Bertrand G, Bonfils S, Boncekknie J (1985) A multicentre controlled trial of ranitidine and cimetidine-resistant peptic ulcer disease. Gastroenterol Clin Biol 9:147–152.PubMedGoogle Scholar
  7. Andersen D, Amdrup E, Hanberg Sorensek F (1990) Parietal cell vagotomy in patients resistant to cimetidine. (in press).Google Scholar
  8. Bader JP, Stanescu L (1989) Problems with patients’ compliance in peptic ulcer therapy. J Clin Gastroenterol [Suppl 1] 11:S25–S28.Google Scholar
  9. Bank S, Barbezat GO, Vinik AI, Helman C (1977) Serum gastrin levels before and after 6 weeks of cimetidine therapy in patients with duodenal ulcer. Digestion 15:157–161.PubMedGoogle Scholar
  10. Bardhan KD (1982) Non-responders to cimetidine treatment. In: Baron JH (ed) Cimetidine in the 80’s. Livingston, Edinburgh, pp 42–57.Google Scholar
  11. Bardhan KD (1984) Refractory duodenal ulcer. Gut 25:711–717.PubMedGoogle Scholar
  12. Bardhan KD (1989) Omeprazole in the management of refractory duodenal ulcer disease. Scand J Gastroenterol [Suppl 166] 24:63–73.Google Scholar
  13. Bardhan KD, Thompson M, Bose K, Hincliffe RFC, Crowe J, Weir DG McCarthy C, Walters J, Thompson TJ, Thompson MH, Gait JE, King C, Prudham D (1987) Combined anti-muscarinic and H2 receptor blockade in the healing of refractory duodenal ulcer. A double blind study. Gut 28:1505–1509.PubMedGoogle Scholar
  14. Bardhan KD, Naesdal J, Bianchi-Porro G, Lazzorini M, Hincliffe RFC, Thompson M, Morris P, Daly MJ, Carroll NJH, Walan A (1988) Treatment of refractory peptic ulcer with omeprazole (Abstr) Gut 29:A724.Google Scholar
  15. Berstad A, Aadland E, Bjerke K (1981) Cimetidine treatment of recurrent ulcer after proximal gastric vagotomy. Scand J Gastroenterol 16:981–986.Google Scholar
  16. Bianchi-Porro G, Parente F, Lazzaroni M (1987) Tripotassium dicitrato bismuthate (TDB) versus two different dosages of cimetidine in the treatment of resistant duodenal ulcers. Gut 28:907–911.PubMedGoogle Scholar
  17. Blair AJ, Richardson CT, Walsh JH, Feldman M (1987) Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology 92:944–949.PubMedGoogle Scholar
  18. Bochnenek WJ, Koronczewski R (1973) Effect of cigarette smoking on bicarbonate and volume of the duodenal contents. Am J Dig Dis 18:729–733.Google Scholar
  19. Boyd EJS, Penston JG, Johnston KA, Wormsley KG (1988) Does maintenance therapy keep duodenal ulcer healed? Lancet 2:134–137.Google Scholar
  20. Brunner G, Creutzfeldt W, Harke U, Lamberts R (1988) Therapy with omeprazole with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion 39:80–90.PubMedGoogle Scholar
  21. Bynum TE, Solomon TE, Johnson LR, Jacobson ED (1972) Inhibition of pancreatic function in man by cigarette smoking. Gut 13:361–365.PubMedGoogle Scholar
  22. Cave DR, Vargas M (1989) Effect of a Campylobacter pylori protein on acid secretion by parietal cell. Lancet 2:187–189.PubMedGoogle Scholar
  23. Cherner JA, Jensen RT, Dubois A, O’Dorisio TM, Gardner JD, Metcalfe DD (1988) Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 95:657–667.PubMedGoogle Scholar
  24. Chiverton SG, Burget D, Hunt RH (1988) Smoking does not impair the response to therapy in duodenal ulcer healing. (Abstr). Gastroenterology 94:A69.Google Scholar
  25. Chiverton SG, Hunt RH (1989) Initial therapy and relapse of duodenal ulcer: possible acid secretory mechanisms. Gastroenterology 96:632–639.PubMedGoogle Scholar
  26. Coghlan JG, Humphries H, Dooley C, Keane C, Gilligan, McKenna D, Sweeney E, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — a 12 month follow up study. Lancet 2:1109–1111.PubMedGoogle Scholar
  27. Collen MJ, Stanczak VJ, Ciarleglio CA (1989) Refractory duodenal ulcers (non healing duodenal ulcers with standard doses of antisecretory medication). Dig Dis Sci 34:233–237.PubMedGoogle Scholar
  28. Dal Monte PR, D’Imperio M, Ferri M, Fratucello F, del Soladato P (1985) A combination of pirenzipine and cimetidine: a new approach to treatment of duodenal ulcer in “non-responders”. Hepatogastroenterology 32:126–128.Google Scholar
  29. Defize J, Goldie J, Hunt RH (1989) Inhibition of acid production by Campylobacter pylori in isolated guinea pig parietal cells. (Abstr). Gastroenterology 96:A114.Google Scholar
  30. Delchier JC, Isal JP, Eriksson S, Soule JC (1989) Double blind multicentre comparison of omeprazole 20mg once daily versus ranitidine 150mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut 30:1173–1178.PubMedGoogle Scholar
  31. Dobrilla G, Vallaperta P, Amplatz S (1988) Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials. Gut 27:106–110.Google Scholar
  32. Domschke W, Lam SK, Pounder RE, Anderson D (1989) H2-blocker resistant duodenal ulceration. Gastroenterol Int 2:85–91.Google Scholar
  33. Feldman M, Colturi TJ (1984) Effect of indomethacin on gastric acid and bicarbonate secretion in humans. Gastroenterology 87:1339–1343.PubMedGoogle Scholar
  34. Feldman M, Richardson CT (1986) Total 24-hour gastric acid secretion in patients with duodenal ulcer. Comparison with normal subjects and effects of cimetidine and parietal cell vagotomy. Gastroenterology 90:540–544.PubMedGoogle Scholar
  35. Feldman M, Richardson CT, Walsh JH (1983) Sex related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest 71:715–720.PubMedGoogle Scholar
  36. Freston JW (1987a) H2-receptor antagonist and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection. Am J Gastroenterol 82:1242–1249.PubMedGoogle Scholar
  37. Freston JW (1987b) Mechanisms of relapse in peptic ulcer disease. J Clin Gastroenterol [Suppl 1] 11:S34–S38.Google Scholar
  38. Frislid K, Aadland E, Berstad A (1986) Augmented postprandial gastric acid secretion due to exposure to ranitidine in healthy subjects. Scand J Gastroenterol 21:119–122.PubMedGoogle Scholar
  39. Fullarton AM, McLaughlin G, MacDonald A, Crean GP, McColl KEL (1989) Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut 30:449–454.PubMedGoogle Scholar
  40. Gledhill T, Buck M, Hunt RH (1983) Cimetidine or vagotomy? Comparison of the effects of proximal gastric vagotomy, cimetidine and placebo on nocturnal intragastric acidity and acid secretion in patients with cimetidine resistant duodenal ulcer. Br J Surg 70:704–706.PubMedGoogle Scholar
  41. Gledhill T, Buck M, Hunt RH (1984) Effect of no treatment, cimetidine 1g/day, cimetidine 2g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders. Gut 25:1211–1216.PubMedGoogle Scholar
  42. Goodwin CS (1988) Duodenal ulcer, Campylobacter pylori leaking and the “roof” concept. Lancet 2:1467–1469.PubMedGoogle Scholar
  43. Goodwin CS, Armstrong JA, Marshall BJ (1986) Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 39:353–365.PubMedGoogle Scholar
  44. Goren A (1989) Campylobacter pylori and acid secretion (Letter). Lancet 2:212–213.Google Scholar
  45. Graham DY (1989) Campylobacter pylori and peptic ulcer disease. Gastroenterology 96:70–90.Google Scholar
  46. Guslandi M (1988) How does smoking harm the duodenum? Br J Med 296:311–312.Google Scholar
  47. Guslandi M, Ballarin E, Tittobello A (1983) Sucralfate in refractory duodenal ulcers. (Abstr). Gut 24:A498.Google Scholar
  48. Halter F (1988) Mechanism of gastrointestinal toxicity of NSAIDs. Scand J Rheumatol [Suppl] 73:16–21.Google Scholar
  49. Halter F, Bangerter U, Häcki WH, Schlup M, Varga L, Wyder S, Rotzer A, Galeazzi R (1982) Sensitivity of the parietal cell to pentagastrin in health and duodenal ulcer disease: A reappraisal. Scand J Gastroenterol 17:539–544.PubMedGoogle Scholar
  50. Hansen JH, Knigge U (1984) Failure of proximal gastric vagotomy for duodenal ulcer resistant to cimetidine. Lancet 2:84–85.PubMedGoogle Scholar
  51. Hirschowitz BI (1984) Apparent and intrinsic sensitivity to pentagastrin of acid and pepsin secretion in peptic ulcer. Gastroenterology 86:843–851.PubMedGoogle Scholar
  52. Humphreys H, Bourke S, Dooley C, McKenna D, Power B, Keane CT, Sweeney EC, O’Morain C (1988) Effect of treatment on Campylobacter pylori in peptic disease: a randomized prospective trial. Gut 29:279–283.PubMedGoogle Scholar
  53. Hunt RH (1981) Non-responders to cimetidine treatment. In: Baron JH (ed) Cimetidine in the 80’s. Livingstone, Edinburgh, pp 331–341.Google Scholar
  54. Hunt RH (1988) Acid suppression and ulcer healing: dichotomy, degree, and dilemma. Am J Gastroenterol 83:964–966.PubMedGoogle Scholar
  55. Hunt RH, Howden CW, Jones DB, Burgett DW, Kerr GD (1986) The correlation between acid suppression and peptic ulcer healing. Scand J Gastroenterol [Suppl 125] 21:22–29.Google Scholar
  56. Hyman PE, Abrams C, Garvey TQ (1985) Ranitidine tachyphylaxis (Abstr). Gastroenterology 88:1426.Google Scholar
  57. Isenberg JI, Grossman MI, Maxwell V, Walsh JH (1975) Increased sensitivity to Stimulation of acid secretion by pentagastrin in duodenal ulcer. J Clin Invest 55:330–337.PubMedGoogle Scholar
  58. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH (1987) Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 28:1120–1127.PubMedGoogle Scholar
  59. Jones DB, Howden CW, Burget DW, Siletti C, Hunt RH (1988) Alteration of H2 receptor sensitivity in duodenal ulcer patients following maintenance treatment with an H2 receptor antagonist. Gut 29:890–893.PubMedGoogle Scholar
  60. Katzenstein ALA, Maksen J (1974) Candida infection of gastric ulcer. Histology, incidence and clinical significance. Am J Clin Pathol 71:137.Google Scholar
  61. Kauffman G (1989) Aspirin-induced gastric injury: lessons learned from animal models. Gastroenterology 96:606–614.PubMedGoogle Scholar
  62. Kohn Y, Misahi F, Kawai K (1972) Endoscopic follow-up observation of duodenal ulcer. Endoscopy 4:202–208.Google Scholar
  63. Konturek SJ, Obtulowicz W, Kweicien N, Kopp B, Oleksy J (1981) Dynamics of gastric acid inhibition by ranitidine in duodenal ulcer patients. Digestion 22:119–125.PubMedGoogle Scholar
  64. Konturek SJ, Radecki T, Piastucki I, Drozdowicz D (1986) Advances in the understanding of the mechanism of cytoprotective action of colloidal bismuth subcitrate. Scand J Gastroenterol [Suppl 122] 21:6–10.Google Scholar
  65. Konturek SJ, Dembinski A, Warzecha Z, Bielanski W, Brzorowski T, Dorozdowilz D (1988) Epidermal growth factor in the gastroprotection and ulcer healing action of colloidal bismuth subcitrate. Gut 29:894.PubMedGoogle Scholar
  66. Konturek JW, Bielanski W, Konturek SJ, Bogdal J, Oleksy J (1989) Distribution and release of epidermal growth factor in man. Gut 30:1194–1200.PubMedGoogle Scholar
  67. Koo J, Ho J, Lam SK, Wong J, Ong GB (1982) Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 82:864–870.PubMedGoogle Scholar
  68. Korman MG, Hansky J, Eaves ER, Schmidt GT (1983) Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 85:871–874.PubMedGoogle Scholar
  69. Kurata JH (1989) Ulcer epidemiology: an overview and proposed research framework. Gastroenterology [Suppl 2] 96:569–580.Google Scholar
  70. Lam SK (1985) Heterogeneous nature of hyperacidity in duodenal ulcer Krevning J, Samloff, Rotter J, Eriksson AW (eds). In: Pepsinogens in man: clinical and genetic advances. Arliss, New York, pp 255–271Google Scholar
  71. Lam SK, Koo J (1985) Gastrin sensitivity in duodenal ulcer. Gut 26:485–490.PubMedGoogle Scholar
  72. Lam SK, Koo J (1983) Accurate prediction of duodenal-ulcer healing rate by discriminant analysis. Gastroenterology 85:403–412.PubMedGoogle Scholar
  73. Lam SK, Lee NW, Koo J, Hui WM, Fok KH, Ng M (1984) Randomized crossover trial of tripotassium dicitrato bisumthate versus high dose cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut 25:703–706.PubMedGoogle Scholar
  74. Langman MJS (1989) Epidemiological evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology 96:640–646.PubMedGoogle Scholar
  75. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NAF, Raymond F, Olausson M, Cedeberg C (1987a) Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1:239–251.PubMedGoogle Scholar
  76. Lanzon-Miller S, Pounder RE, Chronos NAF, Hamilton M, Ball S, Raymond F (1987b) Can high dose ranitidine eliminate intragastric acid and what does it do to plasma gastrin? (Abstr). Gastroenterology 92:1491.Google Scholar
  77. Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam J (1989) Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 2:1467–1469.Google Scholar
  78. Levine RA, Schwartzel EH (1984) Effect of indomethacin on basal and histamine stimulated gastric acid secretion. Gut 25:718–722.PubMedGoogle Scholar
  79. Lewin KJ, Yang K, Ulich T, Glashoff, Walsh J (1984) Primary gastrin cell hyperplasia: a report of five cases and review of the literature. Am J Surg Pathol 8:821–832.PubMedGoogle Scholar
  80. MacCarthy DM (1984) Smoking and ulcers — time to quit. N Engl J Med 311:726–728.Google Scholar
  81. Marks IN, Young GO, Tigler-Wybrandi NA, Bridger S, Newton KA (1989) Acid secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after healing with sucralfate or ranitidine. Am J Med [Suppl 6A] 86:145–147.Google Scholar
  82. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1:1312–1315.Google Scholar
  83. Marshall BJ, Goodwin CS, Warren JE, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2:1437–1442.PubMedGoogle Scholar
  84. McCready DR, Clark L, Cohen MM (1985) Cigarette smoking reduces human gastric luminal Prostaglandin E2. Gut 26:1192–1196.PubMedGoogle Scholar
  85. McLean AJ, Harrison PM, Ionnides-Demos L, Byrne AJ, McCarthy P, Dudley FJ (1985) The choice of ulcer healing agent influences ulcer healing rate and long term clinical outcome. Aust N Z J Med 15:367–374.PubMedGoogle Scholar
  86. McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikan V, Lister DM, Wise R (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 293:645–649.Google Scholar
  87. Mignon M, Bonfils S (1988) Diagnosis and treatment of Zollinger-Ellison syndrome. In: Piper DW (ed) Bailliere’s clinical gastroenterology. Balliere Tindall, London, pp 677–689.Google Scholar
  88. Miller JP, Faragher EB (1986) Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J 293:1117–1118.Google Scholar
  89. Nava G, Pippa G, Ballanti R, Papi C, Nava G Jr (1979) Role of ulcer morphology in evaluating prognosis and therapeutic outcome in duodenal ulcer. Scand J Gastroenterol [Suppl 54] 124:41–43.Google Scholar
  90. Newman RD, Gitlin N, Lacayo EJ, Safdi AV, Ramsey EJ, Engel SL, Rubin A, Nissen CH, Swabb EA (1987) Misoprostol in the treatment of duodenal ulcer refractory to H2-blocker therapy. Am J Med [Suppl 1A] 83:27–31.Google Scholar
  91. Nwokolo CU, Smith JTL, Pounder RE (1989a) Rebound intragastric hyperacidity following dosing with cimetidine, nizatidine and famotidine. (Abstr). Gastroenterology 96:A369.Google Scholar
  92. Nwokolo CU, Gavey CJ, Smith JLT, Gavey C, Sawyerr A, Pounder RE (1989b) Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine. (Abstr). Gut 30:A1487.Google Scholar
  93. Nwokolo CU, Smith JLT, Sawyerr A, Pounder RE (1989c) Intravenous pentagastrin can overcome H2 blockade in man: a possible mechanism for tolerance. (Abstr). Gut 30:A1487.Google Scholar
  94. Orlando RC (1987) Peptic ulcer: factors influencing recurrence. Clin J Gastroenterol [Suppl 1] 9:2–7.Google Scholar
  95. Parente F, Lazzaroni M, Sangaletti O, Baroni S, Bianchi Porro G (1985) Cigarette smoking, gastric acid secretions and serum pepsinogen I concentrations in duodenal ulcer patients. Gut 26:1327–1332.PubMedGoogle Scholar
  96. Peters M, Weiner J, Whelan G (1980) Fungal infection associated with gastroduodenal ulceration: Endoscopic and pathologic appearances. Gastroenterology 78:350–354.PubMedGoogle Scholar
  97. Pickard WR, MacKay C (1984) Early results of surgery in patients considered cimetidine failures. Br J Surg 71:67–68.PubMedGoogle Scholar
  98. Piper DW (1987) The refractory ulcer. World J Surg 11:268–273.PubMedGoogle Scholar
  99. Pounder RE (1987) What is an intractable duodenal ulcer and how should it be managed? Aliment Pharmacol Therap 1:4395–4465.Google Scholar
  100. Prichard PJ, Kerr GD (1985) Duodenitis and ulcer relapse. Lancet 2:102.PubMedGoogle Scholar
  101. Prichard PJ, Jones DB, Yeomans ND, Mikaly GW, Smallwood RA, Louis WJ (1986) The effectiveness of ranitidine in reducing gastric acid secretion decreases with continued therapy. Br J Clin Pharmacol 22:663–668.PubMedGoogle Scholar
  102. Primrose JN, Axon ATR, Johnston D (1988) Highly selective vagotomy and duodenal ulcers that fail to respond to H2 receptor antagonists. Br Med J 296:1031–1035.Google Scholar
  103. Quatrini M, Basilico G, Bianchi PA (1984) Treatment of ‘cimetidine-resistant’ chronic duodenal ulcers with ranitidine or cimetidine: a randomised multicentre study. Gut 25:1113–1117.PubMedGoogle Scholar
  104. Quinby GF, Avundk-Bonnice AC, Burstein SH, Eastwood GL (1986) Active smoking depresses Prostaglandin synthesis in human gastric mucosa. Ann Intern Med 104:616–619.Google Scholar
  105. Rack J, Sonnenberg A (1983) The influence of smoking and intravenous nicotine on gastric mucus. Hepatogastroenterology 30:258–260.PubMedGoogle Scholar
  106. Richardson CT (1978) Effect of H2-receptor antagonists on gastric acid secretion and serum gastrin concentration: a review. Gastroenterology 74:366–370.PubMedGoogle Scholar
  107. Santana IA, Lanzon-Miller S, Pounder RE (1986) Effect of oral famotidine on 24-hour intragastric acidity. Postgrad Med J [Suppl 2] 62:39–42.Google Scholar
  108. Scheurer U, Witzel L, Halter F, Keller HM, Huber R, Caleazzi R (1977) Gastric and duodenal ulcer healing under placebo treatment. Gastroenterology 72:838–841.PubMedGoogle Scholar
  109. Schwarz K (1910) Ueber penetrierende Magen-und Jejunalgeschwüre. Beitr Z Klin Chir 67:69–128.Google Scholar
  110. Sewing KF, Hagie L, Ippoliti AF, Isenberg JI, Samloff IM, Sturderant RAL (1978) Effect of one month treatment with cimetidine on gastric secretion and serum gastrin and pepsinogen levels. Gastroenterology 74:376–379.Google Scholar
  111. Sharma BK, Walt RP, Pounder RE, Gomes EFA, Wood EC, Logan LH (1984) Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 25:957–964.PubMedGoogle Scholar
  112. Sharma B, Alexson M, Pounder RE, Lundberg P, Öman M, Sanatana A, Talbot M, Cederberg C (1987) Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Therap 1:67–76.Google Scholar
  113. Smith JLT, Gavey CJ, Nwokolo CU, Pounder RE (1989) Tolerance during eight days of high dose H2 blockade: placebo controlled studies of 24 hour acidity and gastrin. (Abstr). Gut 30:A1487.Google Scholar
  114. Sonnenberg A (1985) Geographic and temporal variations in the occurrence of peptic ulcer disease. (Suppl 10). Scand J Gastroenterol 20:11–24.Google Scholar
  115. Sonnenberg A, Müller-Lissner SA, Vogel E, Schmid P, Gonvers JJ, Peter P, Strohmeyer G, Blum AL (1981) Predictors of duodenal ulcer healing and relapse. Gastroenterology 81:1061–1067.PubMedGoogle Scholar
  116. Sontag S, Graham DY, Belisto A, Belsito A, Weiss J, Farley A, Grunt R, Coben N, Kinnear D, Davis W, Archambault A, Achord J, Thayer W, Gillies R, Sidorov J, Sabesin SM, Dyck W, Fleshier B, Cheator I, Wengen J, Opekun A (1984) Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med 311:689–693.PubMedGoogle Scholar
  117. Szabo S (1987) Mechanisms of mucosal injury in the stomach and duodenum: time-sequence analysis of morphologic, functional, biochemical and histological studies. Scand J Gastroenterol [Suppl 121] 22:21–28.Google Scholar
  118. Thomas JM, Misenwicz JJ (1984) Histamine H2 receptor antagonists in short and long term treatment of duodenal ulcer. Clin Gastroenterol 13:501–505.PubMedGoogle Scholar
  119. Thomas E, Reddy KR (1983) Non-healing duodenal ulceration to Candida. J Clin Gastroenterol 5:55.PubMedGoogle Scholar
  120. Tytgat GNJ, Lamers CBHW, Hameeteman W, Jansen JMBJ, Wilson JA (1987) Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Therap 1:31–38.Google Scholar
  121. Vantini I, Ederlene A, Bovo P, Voama B, Biubello W, Benini L, Carabellini G, Scuoro LA (1987) Serum fasting gastrin levels after short term treatment with cimetidine in patients with duodenal ulcer. Acta Hepato-Gastroenterol (Study) 25:376–379.Google Scholar
  122. Walt RP, Daneshmend TK (1988) Resistant duodenal ulcer: when, why, and what to do? Post Grad Med J 64:369–372.Google Scholar
  123. Weaver RM, Temple JG (1985) Proximal gastric vagotomy in patients resistant to cimetidine. Br J Surg 72:177–178.PubMedGoogle Scholar
  124. Whitfield PF, Hobsley M (1987) Comparison of maximal gastric secretion in smokers and non-smokers with and without duodenal ulcer. Gut 28:557–560.PubMedGoogle Scholar
  125. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Varga L, Röehmel J, Halter F, Merki HS (1989) Acute tolerance to H2 receptor antagonists. Gut 30:A1489.Google Scholar
  126. Wormsley KG (1978) Smoking and duodenal ulcer. Gastroenterology 75:139–142.PubMedGoogle Scholar
  127. Yanaka A, Muto H (1988) Increased parietal cell responsiveness to tetragastrin in patients with recurrent duodenal ulcer disease. Dig Dis Sci 33:1459–1465.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • J. W. Rademaker
  • R. H. Hunt

There are no affiliations available

Personalised recommendations